Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Public Health

The challenge posed by leptospirosis

Erica Weir
CMAJ November 28, 2000 163 (11) 1501;
Erica Weir
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Epidemiology

Each year an international “EcoChallenge” race involving 4-person teams of men and women is held in a different location, with the teams competing in events such as jungle trekking, open-water swimming and spelunking. This year 76 teams from 26 countries competed in the race, which took place in Borneo from Aug. 20 to Sept. 3.

Four days after the race ended, the US Centers for Disease Control and Prevention (CDC) were notified about a case of acute febrile illness in a 35-year-old man who had run in the event.1 The Idaho Department of Public Health reported that his illness was characterized by acute onset of high fever, chills, headache and myalgia. Preliminary laboratory diagnosis indicated that the probable cause was leptospirosis, a spirochete infection transmitted to humans through water contaminated with urine from infected animals.

To identify additional athletes with febrile illness, the CDC conducted a telephone survey of the EcoChallenge participants. By Sept. 13, 37 (45%) of the 82 US athletes who had been contacted reported having a fever and 12 had been admitted to hospital. Serum samples taken in the acute phase obtained from 2 athletes in hospital were tested for leptospirosis by the CDC; the results of both the DIP-S-Assay and the ELISA IgM test were positive in 1 athlete. The results for the other athlete were initially negative, but repeat tests of a specimen obtained 4–6 days following the onset of fever yielded positive results.1

On Sept. 13 the CDC issued an advisory about the probable leptospirosis outbreak associated with the EcoChallenge event. By Sept. 15, 4 of the 20 Canadian participants were being treated presumptively for leptospirosis.2

Clinical management

Leptospirosis may be the world's most widespread zoonosis.3 Although it is endemic in tropical countries such as Brazil, sporadic outbreaks are not uncommon in temperate regions such as the United States.4 Typically, humans are infected through occupational or recreational exposure to water, soil or vegetation contaminated by the urine of infected animals; common reservoirs include swine, cattle, dogs, raccoons and rats. Leptospires enter the body through cut or abraded skin, mucous membranes and conjunctivae and cause vasculitis.

The incubation period ranges from 4 days to 4 weeks. The symptom spectrum is broad. The illness usually begins abruptly with fever, chills, rigours (particularly in the calves and lumbar region) and headaches, and may include conjunctivitis, abdominal pain, vomiting, diarrhea and meningeal signs. The acute septicemia may be followed by a secondary phase of severe disease characterized by jaundice, renal failure, hemorrhage or hemodynamic collapse.4

The organism may be isolated from samples of blood and cerebrospinal fluid obtained during the first 10 days of illness, and in the urine following the first week of illness. The microagglutination test is the standard for serological diagnosis,5 but it can be time consuming and difficult to perform. Physicians who suspect a case of leptospirosis should contact their local medical officer of health or the Population and Public Health Branch (formerly the Laboratory Centre for Disease Control) at Health Canada for advice on sample collection and laboratory confirmation.

The CDC recommends that patients with mild cases be treated with doxycycline (100 mg orally, twice daily for 7 days) and that those admitted to hospital because of persistent fever, hepatic or renal failure or severe neurologic disturbance be treated intravenously with penicillin G (1.5 million units every 6 hours for 7 days).1 However, a recent Cochrane review of the randomized controlled trials in which antibiotics were used to treat leptospirosis6 identified only 3 trials that met inclusion criteria, 2 of which were of questionable quality. The authors of the review concluded that there is insufficient evidence to provide clear guidelines for antibiotic regimens for treating leptospirosis, although the evidence suggests that penicillin “may cause more good than harm.”

Prevention

Chemoprophylaxis for leptospirosis is 200 mg of doxycycline orally once per week.7 The merits of one 200-mg dose of doxycycline orally for postexposure prophylaxis are unknown. Steps to prevent leptospirosis include recognizing and avoiding swimming or wading in contaminated water and wearing protective clothing and gear such as boots, gloves and aprons. Other steps include controlling rodents, immunizing farm animals and pets, and segregating infected domestic animals. For further information see references 8 and 9. —

References

  1. 1.↵
    Public health dispatch: outbreak of acute febrile illness among participants in EcoChallenge Sabah 2000 Malaysia. MMWR 2000;49:816-7.
    OpenUrl
  2. 2.↵
    Population and Public Health Branch. Leptospirosis associated with EcoChallenge Sabah 2000 Race in Malaysia: United States [newsbrief]. Ottawa: Health Canada; 2000 Sept 22. Available: www.hc-sc.gc.ca/hpb/lcdc/bid/dsd/news/nb3800_e.html.
  3. 3.↵
    Plank R, Dean D. Overview of the epidemiology, microbiology, and pathogenesis of Leptospira spp. in humans. Microbes Infect 2000; 2:1265-76.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Outbreak of acute febrile illness among athletes participating in triathlons — Wisconsin and Illinois. MMWR 1998;47:585-8.
    OpenUrlPubMed
  5. 5.↵
    Kauffman A, Weyant R. Leptospiraceae. In: Murray P, Baron E, Pfaller M, Tenover F, Yolken R, editors. Manual of clinical microbiology. 6th ed. Washington: American Society for Microbiology; 1995. p. 621-5.
  6. 6.↵
    Guidugli F, Castro A, Atallah A. Antibiotics for treating leptospirosis [Cochrane Review]. In: The Cochrane Library; Issue 3, 2000. Oxford: Update Software.
  7. 7.↵
    Takafuji E, Kirkpatrick J, Miller R, Karwacki J, Kelley P, Gray M, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med 1984;310:497-500.
    OpenUrlCrossRefPubMed
  8. 8.
    Ostroff S, Kozarsky P. Emerging infectious disease and travel medicine. Infect Dis Clin North Am 1998;12(1):231-41.
    OpenUrlCrossRefPubMed
  9. 9.
    Levett P. Leptospirosis: Re-emerging or re-discovered disease? J Med Microbiol 1999;48:417-8.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 163, Issue 11
28 Nov 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The challenge posed by leptospirosis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
The challenge posed by leptospirosis
Erica Weir
CMAJ Nov 2000, 163 (11) 1501;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
The challenge posed by leptospirosis
Erica Weir
CMAJ Nov 2000, 163 (11) 1501;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Epidemiology
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Scopus
  • Google Scholar

Cited By...

  • No citing articles found.
  • Scopus (2)
  • Google Scholar

More in this TOC Section

  • Seasonal drinking: Let's avoid the “January effect”
  • Influenza in children
  • Latent tuberculosis: revised treatment guidelines
Show more Public Health

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Copyright and Permissions
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2019, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire